MOUNTAIN VIEW, Calif., Oct. 11 /PRNewswire/ -- IRIDEX Corporation (Nasdaq: IRIX) today announced commercial availability of a new family of Adjustable & Intuitive EndoProbe laser handpieces for use with the Company's laser platforms in vitreoretinal surgery. The Adjustable & Intuitive Laser Probes speed up treatments by allowing continuous, intuitive adjustment of the fiber optic over a wide range of angles for full coverage of the peripheral retina without requiring removal and reinsertion of the probe from the eye or requiring frequent adjustments of laser power settings. In addition, its innovative design and construction allows surgeons to treat further away from the retina and/or at a lower power setting.
"The introduction of this product under a newly issued U.S. patent reinforces our strategy of building upon our position as the global leader in laser delivery instrumentation and to continue to increase the value of our consumable instrumentation line," said Theodore A. Boutacoff, President and CEO.
"We will continue to focus on introducing new products that differentiates us from our competitors and leverage our existing sales channel to increase our revenues."
This product is protected by U.S. Patent No. 7,766,904, "Adjustable Laser Probe For Use In Vitreoretinal Surgery." This patent applies to a number of consumable medical devices already in the IRIDEX product line, collectively identified and sold as Adjustable and Intuitive EndoProbe® laser handpieces.
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems and delivery devices. We provide solutions for multiple specialties, including ophthalmology, dermatology and otolaryngology. We maintain a deep commitment to the success of our customers, wi